Key result
ACE inhibitor therapy was associated with a significantly lower incidence of renal events compared to non-ACEI therapy (12.6% vs 20.5%, P=0.0104) in patients with hypertensive nephrosclerosis.
Why the study?
Does antihypertensive therapy containing an ACE inhibitor reduce the incidence of renal events in patients with hypertensive nephrosclerosis?
Population
295 patients with essential hypertension diagnosed as having nephrosclerosis
Comparison
Antihypertensive therapy containing an ACE… vs Antihypertensive therapy without an ACE inhibitor
Design
Cohort
Follow-up
mean 7.4+/-3.9 years
Authors
Loading...
May support ACEI preference in hypertensive nephrosclerosis; extends observational data but leaves causal benefit open.
Cohort (n=295)
Does antihypertensive therapy containing an ACE inhibitor reduce the incidence of renal events in patients with hypertensive nephrosclerosis?
Absolute Event Rate: 12.6% vs 20.5%
p-value: p=0.0104
In patients with hypertensive nephrosclerosis, ACE inhibitor therapy significantly reduces the incidence of renal events independently of blood pressure control.
Segura et al. (2001) conducted a cohort in Hypertensive nephrosclerosis (n=295). ACE inhibitors vs. Non-ACEI antihypertensive therapy was evaluated on Confirmation of a 50% reduction in creatinine clearance or entry in a dialysis program (p=0.0104). ACE inhibitor therapy was associated with a significantly lower incidence of renal events compared to non-ACEI therapy (12.6% vs 20.5%, P=0.0104) in patients with hypertensive nephrosclerosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: